Terminated PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT00981799

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC

Sponsor: GlaxoSmithKline

Conditions Relapsed T-Cell Acute Lymphoblastic Leukemia Relapsed T-Cell Lymphoblastic Lymphoma

Interventions Cyclophosphamide Etoposide Filgrastim Methotrexate Nelarabine

Updated 8 times since 2017 Last updated: Sep 8, 2020 Started: Jun 30, 2010 Primary completion: Nov 30, 2015 Completion: Jul 18, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual rate

Other terminated trials from GlaxoSmithKline

See all terminations from GlaxoSmithKline

A PHASE1/PHASE2 clinical study on Relapsed T-Cell Acute Lymphoblastic Leukemia and Relapsed T-Cell Lymphoblastic Lymphoma, this trial is terminated or withdrawn. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Oct 2020 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2

▶ Show 3 earlier versions

Jun 2018 — Oct 2020 [monthly]

Terminated PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1_PHASE2

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Novartis
Therapeutic Advances in Childhood Leukemia Consortium

Data source: Therapeutic Advances in Childhood Leukemia Consortium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Boston, United States , Brisbane, Australia , Charlotte, United States , Chicago, United States , Cleveland, United States , Columbus, United States and 26 more locations